149 related articles for article (PubMed ID: 36712921)
61. Panel of serum miRNAs as potential non-invasive biomarkers for pancreatic ductal adenocarcinoma.
Khan IA; Rashid S; Singh N; Rashid S; Singh V; Gunjan D; Das P; Dash NR; Pandey RM; Chauhan SS; Gupta S; Saraya A
Sci Rep; 2021 Feb; 11(1):2824. PubMed ID: 33531550
[TBL] [Abstract][Full Text] [Related]
62. Postoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinoma.
Kim J; Lee YS; Hwang IK; Kang BK; Cho JY; Yoon YS; Han HS; Hwang JH
J Korean Med Sci; 2015 Mar; 30(3):259-63. PubMed ID: 25729247
[TBL] [Abstract][Full Text] [Related]
63. Heterogeneity of metabolic adaptive capacity affects the prognosis among pancreatic ductal adenocarcinomas.
Kanda T; Wakiya T; Ishido K; Kimura N; Fujita H; Yoshizawa T; Goto S; Tatara Y; Kijima H; Hakamada K
J Gastroenterol; 2022 Oct; 57(10):798-811. PubMed ID: 35780404
[TBL] [Abstract][Full Text] [Related]
64. Circulating Tumor Cells as a Biomarker in Pancreatic Ductal Adenocarcinoma.
Liu H; Sun B; Wang S; Liu C; Lu Y; Li D; Liu X
Cell Physiol Biochem; 2017; 42(1):373-382. PubMed ID: 28558380
[TBL] [Abstract][Full Text] [Related]
65. Soluble AXL is a novel blood marker for early detection of pancreatic ductal adenocarcinoma and differential diagnosis from chronic pancreatitis.
Martínez-Bosch N; Cristóbal H; Iglesias M; Gironella M; Barranco L; Visa L; Calafato D; Jiménez-Parrado S; Earl J; Carrato A; Manero-Rupérez N; Moreno M; Morales A; Guerra C; Navarro P; García de Frutos P
EBioMedicine; 2022 Jan; 75():103797. PubMed ID: 34973624
[TBL] [Abstract][Full Text] [Related]
66. Biomarkers in pancreatic cancer: diagnostic, prognostic, and predictive.
Fong ZV; Winter JM
Cancer J; 2012; 18(6):530-8. PubMed ID: 23187839
[TBL] [Abstract][Full Text] [Related]
67. Label-free proteomics reveals serum proteins whose levels differ between pancreatic ductal adenocarcinoma patients with short or long survival.
Holm M; Saraswat M; Joenväärä S; Seppänen H; Renkonen R; Haglund C
Tumour Biol; 2020 Jun; 42(6):1010428320936410. PubMed ID: 32586207
[TBL] [Abstract][Full Text] [Related]
68. Serum tumor markers not useful in screening patients with pancreatic mucinous cystic lesions associated with malignant changes.
Pezzilli R; Calculli L; Melzi d'Eril G; Barassi A
Hepatobiliary Pancreat Dis Int; 2016 Oct; 15(5):553-557. PubMed ID: 27733327
[TBL] [Abstract][Full Text] [Related]
69. Prognostic and predictive markers in pancreatic adenocarcinoma.
Le N; Sund M; Vinci A;
Dig Liver Dis; 2016 Mar; 48(3):223-30. PubMed ID: 26769569
[TBL] [Abstract][Full Text] [Related]
70. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
71. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers.
Koopmann J; Buckhaults P; Brown DA; Zahurak ML; Sato N; Fukushima N; Sokoll LJ; Chan DW; Yeo CJ; Hruban RH; Breit SN; Kinzler KW; Vogelstein B; Goggins M
Clin Cancer Res; 2004 Apr; 10(7):2386-92. PubMed ID: 15073115
[TBL] [Abstract][Full Text] [Related]
72. Pancreatic cancer survival prediction via inflammatory serum markers.
Lanki M; Seppänen H; Mustonen H; Salmiheimo A; Stenman UH; Salmi M; Jalkanen S; Haglund C
Cancer Immunol Immunother; 2022 Sep; 71(9):2287-2292. PubMed ID: 35034144
[TBL] [Abstract][Full Text] [Related]
73. MiR-590 Suppresses Proliferation and Induces Apoptosis in Pancreatic Cancer by Targeting High Mobility Group A2.
Wang YD; Mao JD; Wang JF; Xu MQ
Technol Cancer Res Treat; 2020; 19():1533033820928143. PubMed ID: 32588766
[TBL] [Abstract][Full Text] [Related]
74. Potential biomarkers for early detection of pancreatic ductal adenocarcinoma.
Kriz D; Ansari D; Andersson R
Clin Transl Oncol; 2020 Dec; 22(12):2170-2174. PubMed ID: 32447642
[TBL] [Abstract][Full Text] [Related]
75. Development and Multiple Validation of the Protein Multi-marker Panel for Diagnosis of Pancreatic Cancer.
Kim Y; Yeo I; Huh I; Kim J; Han D; Jang JY; Kim Y
Clin Cancer Res; 2021 Apr; 27(8):2236-2245. PubMed ID: 33504556
[TBL] [Abstract][Full Text] [Related]
76. Low Serum miR-607 Level as a Potential Diagnostic and Prognostic Biomarker in Patients of Pancreatic Ductal Adenocarcinoma: A Preliminary Study.
Jiang D; Yuan X; Ni J; Shen L; Cai M; Xu L
Can J Gastroenterol Hepatol; 2021; 2021():8882129. PubMed ID: 34222137
[TBL] [Abstract][Full Text] [Related]
77. Soluble stroma-related biomarkers of pancreatic cancer.
Resovi A; Bani MR; Porcu L; Anastasia A; Minoli L; Allavena P; Cappello P; Novelli F; Scarpa A; Morandi E; Falanga A; Torri V; Taraboletti G; Belotti D; Giavazzi R
EMBO Mol Med; 2018 Aug; 10(8):. PubMed ID: 29941541
[TBL] [Abstract][Full Text] [Related]
78. Noninvasive risk stratification of intraductal papillary mucinous neoplasia with malignant potential by serum apolipoprotein-A2-isoforms.
Felix K; Honda K; Nagashima K; Kashiro A; Takeuchi K; Kobayashi T; Hinterkopf S; Gaida MM; Dang H; Brindl N; Kaiser J; Büchler MW; Strobel O
Int J Cancer; 2022 Mar; 150(5):881-894. PubMed ID: 34778955
[TBL] [Abstract][Full Text] [Related]
79. High expression of RAB38 promotes malignant progression of pancreatic cancer.
Li BY; He LJ; Zhang XL; Liu H; Liu B
Mol Med Rep; 2019 Feb; 19(2):909-918. PubMed ID: 30569114
[TBL] [Abstract][Full Text] [Related]
80. Identification of human complement factor B as a novel biomarker candidate for pancreatic ductal adenocarcinoma.
Lee MJ; Na K; Jeong SK; Lim JS; Kim SA; Lee MJ; Song SY; Kim H; Hancock WS; Paik YK
J Proteome Res; 2014 Nov; 13(11):4878-88. PubMed ID: 25057901
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]